Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Nebraska Only)
UnitedHealthcare Medical Policy for electrical stimulation modalities (TENS, FES, NMES, PENS, PNS, etc.) applicable to Nebraska providers and members; defines coverage rationale, coding references, and devices considered unproven.
Policy Summary
PayerUnitedHealthcare
PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Nebraska Only)
Policy CodePolicy CS036NE.U
Change TypeNo material change
Effective DateMay 1, 2026
Next Review Date
Key ActionDocument prior conservative therapies and objective baseline measures when requesting prior authorization for indication‑specific electrical stimulation therapies.
No material clinical or coverage changes in this revision.
May 1, 2026Effective date
NebraskaApplies to
11 itemsFES criteria
10+Unproven modalities
MultipleBilling codes listed
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
Demonstration of intact lower motor units (L1 and below) (both muscle and peripheral nerves).
Muscle and joint stability for weight-bearing at upper and lower extremities with balance and control to maintain an upright support posture independently.
Demonstration of brisk muscle contraction.
Demonstration of sensory perception sufficient for muscle contraction.
High level of motivation, commitment, and cognitive ability for device use.
Ability to transfer independently.
Demonstration of independent standing tolerance for at least 3 minutes.
Demonstration of hand and finger function to manipulate controls.
Post recovery from SCI and restorative surgery of at least 6 months.
Absence of hip and knee degenerative disease.
Absence of history of long bone fracture secondary to osteoporosis.
TENS and NMES — conditional
TENS and NMES
TENS and NMES: Transcutaneous electrical nerve stimulator (TENS) and neuromuscular electrical stimulation (NMES) are considered medically necessary in certain circumstances; see Nebraska Department of Health and Human Services codes for specific clinical coverage criteria (TENS: Code 471-7-004.02(GGG); NMES: Code 471-7004.02(LL)).
Refer to state code for detailed criteria.
Unproven / Not Medically Necessary
Unproven and not medically necessary for listed indications
Unproven modalities: Interferential therapy (IFT); Microcurrent electrical nerve stimulation (MENS); Percutaneous electrical nerve stimulation (PENS) or percutaneous neuromodulation therapy (PNT); Percutaneous electrical nerve field stimulation (PENFS); Percutaneous peripheral nerve stimulation (PNS)*; Peripheral subcutaneous field stimulation (PSFS) or peripheral nerve field stimulation (PNFS); Pulsed electromagnetic field stimulation (PEMF/PES); Restorative neurostimulation; Scrambler therapy; Translingual stimulation for gait rehabilitation are considered unproven and not medically necessary due to insufficient evidence of efficacy.
See note relating to occipital neuralgia/headache policy for PNS.
FES for Spinal Cord Injury — evidence summary
Evidence conclusions and applicability notes
FES evidence summary for SCI: Systematic reviews and randomized trials report mixed but sometimes positive outcomes for FES in spinal cord injury, including improvements in expiratory function, VO2 peak when combined with exercise, increased muscle cross-sectional area, and some functional gains; overall evidence quality is limited by small sample sizes and heterogeneity of methods.
References: Xiangli et al.; Hayes HTA; Máté et al.; Chen et al.
Limited efficacy in very weak muscles
RCT findings and limitations
Very weak muscles: An 8-week assessor-blinded RCT found negligible effect of strength training combined with electrical stimulation on very weak muscles; limitations included dosing, session frequency, and outcome measure sensitivity.
Chen et al. RCT (8-week)
FES for Cerebral Palsy — trial evidence
FES in cerebral palsy — limited RCT evidence
CP RCT: Small randomized trials and systematic reviews in children with cerebral palsy report FES can increase ankle dorsiflexion angle and strength and improve selective motor control and some gait kinematics, but activity/participation benefits are uncertain and larger trials are needed.
Elsharkawy et al.; Moll et al.
Coverage considerations — mixed evidence
Coverage considerations when evaluating FES for rehabilitation across indications:
General evidence-consideration: Use for specific indications (e.g., foot drop post-stroke, CP-related foot drop, selected SCI rehabilitation) should be supported by indication-specific evidence and objective baseline measures; randomized trials and HTAs report heterogeneous, low-to-moderate quality evidence and inconsistency in functional and quality-of-life benefits.
Hayes HTAs, ECRI, systematic reviews
Situations with some supporting evidence: Assistive FES for foot drop after stroke and FES combined with exercise (e.g., cycling) in early/subacute stroke have trials showing improvements in some gait and aerobic outcomes, but results are inconsistent and not uniformly durable.
Matsumoto et al., Galvão et al., Xiangli et al.
Limitations to consider: Most studies are small, short duration, single-center, use different devices and parameters, and lack long-term (>18 months) outcome data; implanted-electrode evidence is very low quality.
Hayes HTAs and multiple RCT limitations
Evidence summaries by indication
Evidence-based considerations and observed outcomes (no explicit policy criteria in this excerpt):
General evidence considerations: Evidence quality varies by indication; many studies are small, heterogeneous, and have limited blinding and follow-up. Benefits are condition- and device-specific; higher-quality RCTs are often recommended.
See cited systematic reviews and HTAs for details.
Neurologic indications (stroke, MS): FES/NMES may improve motor scores, ankle dorsiflexion, balance, and functional mobility when combined with supervised therapy; superiority over conventional therapy is inconsistent and may depend on timing (acute/subacute vs chronic).
Multiple systematic reviews and RCTs cited.
Cardiac (CHF): FES of lower limbs can improve peak VO2, 6-minute walk distance, and quality of life compared with control, though traditional exercise may outperform FES for some metrics.
Zeng et al.; Kadoglou et al.
Evidence summaries by indication
Evidence findings summarized by condition and study type
Musculoskeletal post‑operative/rehab findings: RCTs of NMES after orthopedic procedures show mixed short-term benefits (pain, edema, femoral vein peak velocity) with small samples and short follow-up; larger trials needed.
THR and ACL studies
Amputation and ACL reconstruction: Small RCTs/pilot studies report NMES may preserve or accelerate quadriceps strength recovery when added to rehabilitation, though clinical relevance and durability require further research.
Talbot et al.; Wellauer et al.
Cerebral palsy: Systematic reviews and RCTs indicate NMES-assisted strengthening and gait training can improve muscle physiology and some gait outcomes in pediatric CP; optimal dosing and long-term effects remain uncertain.
Greve et al.; Pool et al.; Moll et al.
Indication-specific evidence summaries
Summary of effectiveness and applicability by clinical condition (evidence-based statements as reported):
Post-stroke (upper extremity and dysphagia): NMES shows potential benefit for activities of daily living post-stroke and for dysphagia when combined with conventional therapy; contralaterally controlled FES (CCFES) may improve manual dexterity versus cNMES in some trials; evidence limited by heterogeneity and risk of bias.
NICE and AHA/ASA guidance note uncertainty and call for further research.
COPD / Respiratory failure / Mechanical ventilation: NMES combined with pulmonary rehabilitation can improve some muscle strength and exercise capacity metrics in selected COPD populations; NMES alone should not replace pulmonary rehabilitation.
Liou et al.; Gutiérrez-Arias et al.
Cystic Fibrosis (pediatric): Small RCTs show no additional cardiorespiratory benefit of adding NMES to resistance training in mild-to-moderate pediatric CF though both groups improved strength.
Jin et al.
Coverage rationale
Summary of coverage-relevant evidence and guideline stance
Evidence synthesis for IFT: Systematic reviews and meta-analyses show mixed results for interferential therapy (IFT): some report short-term pain/function improvement for knee OA while broader reviews and guideline panels (NICE, ACP) found insufficient evidence to support routine use; heterogeneity of devices and protocols is a major limitation.
Hussein et al.; Chen et al.; NICE; ACP
Guideline recommendations: NICE recommends against offering IFT for osteoarthritis and chronic primary pain and recommends NMES for dysphagia only with special arrangements; ACP finds insufficient evidence for IFT in low back pain—guideline conclusions may inform noncoverage or restrictions.
NICE guidance and ACP statements
Trial-level negative findings: Multiple randomized trials (e.g., post-TKA, shoulder, proximal humerus fracture) showed no significant benefit of IFT or MENS over sham or alternative modalities for primary outcomes; small sample sizes and short follow-up limit generalizability.
Kadı et al.; Duran et al.; other RCTs cited
Coverage stance and conditional criteria
Evidence summary and conditional coverage stance based on the cited literature and guidelines in this segment
Evidence summary: Available evidence for MENS, PENS, and PENFS is largely small RCTs, registries, and observational studies with short-term follow-up; some show short-term pain reduction but long-term benefits are unproven and heterogeneity is high.
Multiple systematic reviews and Hayes brief
Guideline recommendations: NICE recommends against PENS for low back pain; specialty guidelines vary with some support (e.g., AAN/AANEM/AAPMR for PDN) but overall recommendations are conditional and limited by evidence quality.
NICE; AAN/AANEM/AAPMR
Conditional use considerations: If considered, PENS/PENFS should be used only after documented trial of conservative therapies, with defined indication, baseline pain measures, anatomical target, and specified session counts; authorization should be individualized pending higher-quality evidence.
Derived from trial inclusion criteria and HTA recommendations
Study-derived candidate coverage criteria
Typical trial-based inclusion/conditions that inform coverage decisions (derived from studies):
PENFS postoperative trial entry conditions: Adult trials commonly required age ≥18, standard perioperative analgesia before enrollment, and excluded chronic opioid use, neuromuscular deficits, bleeding/anticoagulation, pregnancy, and pacemaker use; auricular devices were left in situ for 5 days in postoperative trials.
Ilfeld et al.; Chogle et al.
PENFS pediatric DGBI typical conditions: Pediatric registries included children meeting Rome criteria for DGBIs, often after failure of multiple pharmacologic therapies, with therapy durations commonly 4–12 weeks and follow-up assessments for symptom indices.
Chogle et al.
PNS candidate criteria from evidence: Adults with chronic neuropathic or persistent postoperative pain refractory to conventional medical management (documented failure of CMM) are typical trial candidates; responder outcomes commonly defined as ≥30% or ≥50% pain reduction.Responder thresholds used in studies (e.g., ≥50% pain reduction)
Implantable PNS after conservative therapy
Covered when ALL of the following are met (per guideline-based support):
ASIPP-based implantable PNS candidate: Patient has moderate to severe chronic pain refractory to two or more conservative treatments as defined in ASIPP guidelines; implantation considered after documented failure of conservative therapies.
ASIPP guideline (Manchikanti et al.)
Temporary (60-day) PNS trial evidence
Covered when ALL of the following are met (per ASIPP supporting statement for temporary PNS):
Temporary percutaneous PNS trial: Patient underwent a temporary percutaneous PNS trial (commonly up to 60 days) with documented responder-level improvement during the trial period.e.g., ≥50% pain reduction during weeks 5–8
ASIPP cites temporary 60-day PNS as supported with level III evidence
PEMF — Evidence-based coverage considerations
Summary of evidence-based coverage considerations for PEMF therapy across indications
Non-specific low back pain (adjunct): PEMF appears safe and may enhance pain relief and function as an adjunct to conventional physical therapy in some small RCTs, but heterogeneity and short follow-up limit certainty; consider coverage only after documented trial of conventional PT.evidence: Kull et al. 9 RCTs; 5/9 showed significant pain benefit
Kull et al.; Markovic et al.
Osteoarthritis (knee and other joints): PEMF may provide short-term pain reduction and functional improvement for knee OA in some RCTs and reviews, particularly with 4–6 week regimens, but inconsistent results and small trials limit definitive conclusions.evidence: Yang et al. meta-analysis (16 RCTs)
Yang et al.; Chen et al.
Acute fracture healing: RCT evidence to date does not demonstrate consistent benefit of PEMF for fracture union; routine use to enhance bone healing is not supported by current trials.
Coverage considerations for restorative neurostimulation (ReActiv8) in mechanical chronic low back pain associated with multifidus dysfunction
Eligibility for restorative neurostimulation: Patient has mechanical chronic low back pain associated with multifidus dysfunction, documented failure of conservative and interventional therapies (including >90 days of medical management and at least one course of physical therapy), baseline ODI and NRS consistent with trial populations (e.g., ODI 30–60, NRS 6–9), and appropriate candidate evaluation documented.RESTORE/ReActiv8 trial enrollment criteria
RESTORE trial inclusion and ReActiv8 PMA criteria
Expected benefit: Randomized trial evidence (RESTORE) demonstrated significantly greater improvements in ODI, NRS, and HRQOL at 1 year with restorative neurostimulation versus OMM; a clinically meaningful composite response occurred in a majority of treated participants.RESTORE trial results (e.g., 72% composite response in treatment vs 11% control)
Schwab et al.; Gilligan et al.
ReActiv8 candidate characteristics (trial-based)
Populations studied in restorative neurostimulation trials (may inform coverage criteria):
ReActiv8 trial-like candidacy: ALL of the following: chronic mechanical CLBP refractory to conservative care (>90 days medical management and at least one attempt of physical therapy); impaired multifidus control evidenced by imaging or physiologic testing; baseline pain and disability in the moderate-to-severe range consistent with trial enrollment; not a candidate for spine surgery or SCS in many studies.
Derived from ReActiv8 trial inclusion and postmarket studies
Scrambler therapy studied indications
Scrambler therapy research contexts (may inform limited/experimental coverage decisions):
Scrambler therapy studied indications: Scrambler therapy has been evaluated for chemotherapy‑induced peripheral neuropathy (CIPN), painful diabetic neuropathy, burn-related neuropathic pain, postsurgical neuropathic pain, cancer pain, and persistent nonspecific low back pain in small RCTs and observational studies; evidence is heterogeneous and generally low quality.
Jin et al.; Hayes reviews; Lee et al.
Scrambler therapy: evidence and guideline-informed stance
Summary of available evidence and guideline positions
Scrambler therapy evidence summary: Randomized trials and systematic reviews show mixed, mostly low-quality evidence for scrambler therapy in neuropathic pain; small RCTs report short-term pain reductions but limited follow-up and methodological limitations predominate.
Hayes; Karri et al.; Jin et al.
Guideline recommendation: Major guideline bodies (ASCO; ESMO/EONS/EANO) do not recommend scrambler therapy for CIPN outside clinical trials due to low strength of evidence or provide a grade indicating not recommended; consider research-only or trial contexts.
ASCO and ESMO guidance
Translingual stimulation (PoNS): evidence summary
Summary of PoNS (translingual stimulation) evidence in mmTBI and MS
PoNS evidence summary: RCTs and pilot studies report improvements in balance and gait when PoNS is combined with targeted physical therapy in mmTBI and MS populations, but trials are limited by small samples, variable controls, potential investigator/developer conflicts, and limited long-term data; additional high-quality trials are recommended.
Ptito et al.; Tyler et al.; Leonard et al.; Chu et al.
Device-specific coverage conditions for restorative neurostimulation (per ReActiv8 PMA indication):
ReActiv8 PMA indication criteria: Adult patients with intractable chronic low back pain associated with multifidus muscle dysfunction demonstrated by imaging or physiologic testing; failure of therapy including pain medications and physical therapy; bilateral stimulation of the L2 medial branch as it crosses the transverse process at L3 as indicated in the PMA; not candidates for spine surgery.
ReActiv8 PMA summary (product code QLK)
Peripheral nerve stimulation (PNS) is listed in this policy as unproven and not medically necessary for indications other than the occipital neuralgia/headache context referenced in a separate Nebraska policy. The policy explicitly includes PNS among modalities judged to have insufficient evidence of efficacy and notes that published studies for many PNS applications are small, heterogeneous, and of low quality, requiring additional high-quality trials to support routine coverage.
Within the excerpt provided there are no explicit procedural exclusions listed for specific devices or CPT/HCPCS codes. The document does identify many modalities as unproven or not medically necessary due to insufficient evidence, but it does not present a separate, named list of coverage exclusions tied to billing codes in the included chunks.
Evidence on implanted-electrode FES is described as very low quality in cited HTAs and reviews; the policy notes limited, small studies and heterogeneity of methods but does not state an explicit procedural exclusion for implanted-electrode FES. Rather, it characterizes implanted-electrode FES evidence as very low quality and indicates additional robust RCTs are needed to establish benefit.
Device-specific claims (for example, the MyndMove system) are described as supported only by small, single-center, unblinded trials; the policy states the evidence is inconclusive and recommends larger, multicenter RCTs before broader adoption. Such device-specific uses are therefore considered experimental/insufficiently supported unless stronger evidence emerges.
For masticatory muscle interventions the evidence is limited: systematic review findings were of very low certainty and concluded there is insufficient evidence to support botulinum toxin or masticatory strengthening programs alone or combined with NMES for this indication. The policy therefore regards these approaches as unsupported by current high‑quality evidence.
NICE guidance is cited recommending that NMES should not be routinely offered for knee osteoarthritis. The policy references NICE conclusions that electrotherapy evidence for OA is inconsistent and generally does not support routine NMES use for knee OA.
The policy cites NICE guidance that interferential therapy (IFT) should not be offered for osteoarthritis and for chronic primary pain; systematic reviews summarized in the document similarly conclude IFT lacks sufficient high-quality evidence to support routine use for OA and chronic primary pain.
NICE explicitly recommends against the use of PENS for low back pain with or without sciatica because of limited and low-quality evidence. The policy notes that PENS is not supported as a routine therapy for LBP per NICE guidance.
Clinical trials described in the policy commonly excluded participants with conditions that could affect safety or interpretability of results, including chronic opioid use or opioid misuse history, bleeding disorders/anticoagulation, neuromuscular deficits, pregnancy, skin abnormalities, and presence of implanted electrical devices (e.g., pacemaker).
Hayes evidence summaries and device‑specific reviews are cited for multiple systems (e.g., StimRouter, Nalu), and for certain indications Hayes found no or unclear support. The policy highlights that some implantable PNS systems and indications currently lack sufficient, high‑quality evidence to support routine use.
Systematic reviews of PEMF for acute fracture healing found only a few small RCTs and no consistent statistically significant effect on fracture union; the policy states routine use of PEMF to enhance bone healing in acute fractures is not recommended.
The policy synthesizes evolving evidence reviews (Hayes, ECRI) and notes that these organizations report insufficient or weak guideline support and inconclusive evidence across broader patient populations, underscoring limitations in study design, small sample sizes, and lack of active‑comparator trials.
Systematic reviews and guideline assessments summarized in the policy conclude that scrambler therapy evidence is low or very low quality and inconsistent; ASCO and other guideline groups do not recommend scrambler therapy for chemotherapy‑induced peripheral neuropathy (CIPN) outside clinical trials.
The policy states that no peripheral nerve field stimulation devices have specific approvals for pain or muscle rehabilitation and that studies have typically used implants intended for spinal cord stimulation off‑label; device approvals for peripheral subcutaneous field stimulation are not identified in the cited material.
The document references guidance and assessments that are jurisdiction‑specific (for example, Nebraska DHHS and NICE), and the policy text notes that some recommendations and coverage decisions may vary by state or by the referenced national guideline bodies.
Across the policy the following modalities are repeatedly referenced: TENS, NMES, FES, PENS, PENFS, PNS, PNFS/PSFS, PEMF/PES, restorative neurostimulation (ReActiv8), scrambler therapy, and translingual stimulation (PoNS). Many of these modalities are discussed in evidence summaries and in statements about insufficient or mixed evidence.
An RCT cited in the policy reported that an 8‑week strength training program combined with electrical stimulation produced a negligible effect on very weak muscles, with limitations noted related to dose, session frequency, and sensitivity of outcome measures.
The policy emphasizes that use of FES for broad claims of improved functional recovery or general quality of life without indication‑specific supporting evidence is not recommended; high‑quality, indication‑specific trials demonstrating durable functional benefit are needed before routine coverage for broad recovery claims.
The policy cautions that devices and systems with limited, small, or low‑quality evidence should be used cautiously. For many PNS systems the evidence base is insufficient or heterogeneous, so routine coverage is not supported without stronger, comparative data and consistent trial‑level outcomes.
Interferential therapy (IFT) is described as having insufficient evidence to support use for musculoskeletal pain, fractures, or to facilitate nonsurgical soft tissue healing. Multiple reviews and guidelines conclude that IFT does not have reliable evidence of added benefit versus standard care.
The policy states that IFT is not supported as medically necessary when added to standard treatment without demonstrated incremental benefit; NICE and ACP guidelines are cited as finding insufficient evidence and recommending against routine offering of IFT for several indications.
Evidence quality for PENS is characterized as low or insufficient to support it as a standalone recommended therapy for chronic low back pain. Given these limitations, PENS is not recommended as first‑line monotherapy and would typically require prior conservative therapy and stronger supporting evidence for routine coverage.
For many PNS systems the policy notes insufficient or low‑quality evidence; systematic reviews and HTAs (Hayes, ECRI) identify methodological weaknesses and small sample sizes, and the policy states that routine coverage is not supported by consistent high‑quality evidence.
Hayes reviews and evidence briefs found insufficient or unclear support for several implantable PNS systems and for some indications (e.g., certain chronic peripheral pain applications); the policy highlights the need for larger, well‑designed trials to clarify efficacy and selection criteria.
Based on systematic review findings, PEMF should not be routinely used to enhance bone healing in acute fractures because RCTs did not demonstrate consistent benefits and the number of trials is small with heterogeneous protocols.
ECRI and Hayes evidence assessments are cited as concluding that the current ReActiv8 and restorative neurostimulation literature is limited by small studies, risk of bias, and inconsistent quality; both organizations described the evidence as inconclusive or weak and called for more rigorous trials.
Systematic reviews and meta-analyses summarized in the policy conclude the evidence for scrambler therapy is low and inconsistent. The policy cites that larger, well‑designed RCTs are needed before scrambler therapy can be recommended for routine clinical use in chronic or cancer‑related pain.
The policy notes that use of spinal cord stimulation implantable pulse generators as peripheral nerve field stimulation is an off‑label application; no dedicated peripheral subcutaneous field stimulation devices have explicit FDA approvals for that indication in the cited material.
Billing Codes and Device Product Codes
Selected CPT codesCPT
0278T
Transcutaneous electrical modulation pain reprocessing (e.g., scrambler therapy), each treatment session (includes placement of electrodes).
0783T
Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment.
63650
Percutaneous implantation of neurostimulator electrode array, epidural.
63655
Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.
63663
Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed.
63664
Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed.
63685
Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
Percutaneous electrical nerve field stimulation, cranial nerves, without implantation.
Additional CPT codesCPT
64596
Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.
64597
Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; each additional electrode array (List separately in addition to code for primary procedure).
64598
Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator.
64999
Unlisted procedure, nervous system.
HCPCS / A / E codesHCPCS
A4438
Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each.
A4543
Supplies for transcutaneous electrical nerve stimulator, for nerves in the auricular region, per month.
A4544
Electrode for external lower extremity nerve stimulator for restless legs syndrome.
A4556
Electrodes (e.g., apnea monitor), per pair.
A4557
Lead wires (e.g., apnea monitor), per pair.
A4593
Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, controller.
A4594
Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece, each.
A4595
Electrical stimulator supplies, 2 lead, per month, (e.g., TENS, NMES).
Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686
Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
L8687
Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688
Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension.
S8130
Interferential current stimulator, 2 channel.
S8131
Interferential current stimulator, 4 channel.
No explicit CPT/HCPCS/ICD codes listed in this extractmixed
No codes listed
Device product codes (FDA references)mixed
GZI
FDA device product code for functional electrical stimulation (search reference)
IPF
FDA device product code for neuromuscular electrical stimulation for muscle rehabilitation
LIH
FDA device product code for interferential therapy devices
ILX
FDA device product code for pulsed electromagnetic field stimulation devices
Device product codes referencedmixed
LIH
Product code referenced for interferential therapy devices
ILX
Product code referenced for pulsed electromagnetic field stimulation devices
NHI
Product code referenced for percutaneous/peripheral nerve stimulation devices
GZB
Product code referenced for percutaneous/peripheral nerve stimulation devices
GZF
Product code referenced for percutaneous/peripheral nerve stimulation devices
LGW
Product code referenced for peripheral nerve field stimulation devices / PMA search
GZJ
Product code referenced for TENS and Scrambler Therapy devices
NUH
Product code referenced for TENS
NGX
Product code referenced for TENS
QHH
Product code referenced for IB-Stim percutaneous electrical nerve field stimulation (DEN180057)
1–10 of 13
1/2
inv-58: Post-recovery from SCI and restorative surgery — example timing
Post-recovery minimum>= 6 months post‑recovery from SCI or restorative surgery
ContextRequired as part of FES candidacy for ambulation rehabilitation in individuals with lower‑limb paralysis due to SCI
Source guidanceSpecified in FES coverage criteria listing clinical eligibility requirements
inv-59: Independent standing tolerance — example threshold
Independent standing tolerance>= 3 minutes of unsupported standing
Prior Authorization, Documentation, Step Therapy, and Denial Risk
Note
No prior authorization statements in this excerpt
No prior authorization statements are present in the examined excerpt of this policy. Where prior authorization is recommended or expected, clinicians should follow payer-specific submission processes.
No explicit universal prior authorization statement in this excerpt
Indication-specific prior authorization is recommended for implantable and high-cost neuromodulation therapies, and for devices with limited or mixed evidence bases (for example, implantable PNS systems, ReActiv8 restorative neurostimulation, and scrambler therapy). Prior authorization requests should reference guideline-endorsed indications where applicable (e.g., ASIPP for PNS, FDA indication for ReActiv8).
Implantable PNS — consider prior authorization with documentation of conservative therapy failure and trial response
ReActiv8/restorative neurostimulation — prior authorization recommended referencing trial enrollment criteria and conservative management history
Conservative Therapy and Stepwise Requirements
Document prior use of AFO or supervised PT when applicable
Document prior AFO or supervised PT use: Document prior use of an ankle-foot orthosis (AFO) or enrollment in supervised physical therapy when applicable, particularly for foot‑drop management where comparative evidence exists versus FES.
Comparative studies suggest AFO or supervised PT be considered prior to long-term device implantation.
Prior use of or concurrent enrollment in supervised conventional rehabilitation is commonly part of trial designs
Prior/concurrent supervised rehabilitation: Prior use of or concurrent enrollment in supervised conventional rehabilitation (physical and occupational therapy) is commonly required or included in trial designs and is reasonable to document before device-only coverage for FES/NMES interventions.
Many RCTs evaluated FES/NMES as adjunct to supervised therapy.
Conservative therapies are preferred first-line per ACP and NICE
Session Durations, Trial Lengths, and Device Timing
inv-177: Implantation, revision, and device supply codes listed; frequency limits not specified
Implantation and revision codesCPT/HCPCS/L-code groups listed for implantation, revision, and device supplies (see coding section: selected CPTs, additional CPTs, HCPCS, L-codes)
Examples of supply codesL8678, L8679, L8680, L8685–L8688 (implantable neurostimulator supplies and pulse generators)
Frequency limitsNo explicit frequency limits specified for implantation, revision, or device supply codes in this segment
inv-178: PNS, Peripheral Nerve Field Stimulation (label reference)
PNS definitionPeripheral nerve stimulation (PNS): electrode(s) implanted or placed near a peripheral nerve to disrupt pain signal transmission
PNFS definition
Imaging and Procedural Guidance Considerations
Note
Note
Note
Note
Note
Note
Note
Note
Not Medically Necessary / Experimental Uses
The policy includes a placeholder style list of modalities identified as not medically necessary in the excerpt, which encompasses many electrotherapy and neuromodulation approaches noted elsewhere in the document.
A duplicate placeholder entry reiterates that a number of electrotherapy modalities are considered not medically necessary in the provided excerpt.
Another duplicate placeholder entry reflects the policy's listing of several modalities judged to be not medically necessary due to limited evidence.
Yet another placeholder duplicate reiterates the set of modalities described as unproven or not medically necessary in the excerpted content.
This placeholder duplicate continues to reflect the policy's grouping of multiple electrotherapy modalities as not medically necessary within the excerpt.
A further placeholder duplicate repeats the policy listing of unproven neuromodulation and electrotherapy modalities considered not medically necessary in the provided text.
This placeholder duplicate entry reiterates the policy's classification of numerous electrical stimulation modalities as not medically necessary given current evidence limitations.
Definitions of Modalities and Terms
inv-122: FES definition
FES definitionDirect application of electric current to intact nerve fibers to cause involuntary but purposeful muscle contraction to enable functions such as standing and ambulation
Delivery methodsElectrodes may be surface electrodes or surgically implanted along with a stimulator
Therapeutic vs functionalTherapeutic FES enables resistive exercise; functional FES enables activities like standing, walking, grasping, respiration
inv-123: NMES
NMES definitionTranscutaneous application of electrical currents to cause muscle contractions to promote reinnervation, prevent atrophy, relax spasms, and promote voluntary muscle control
Typical uses
Procedure Codes, Frequency Notes and Device Timing (Metadata)
inv-177: Implantation, revision, and device supply codes listed; frequency limits not specified in this segment
Implantation/revision codes include imaging guidance when performedCPT codes for neurostimulator electrode implantation/revision reference fluoroscopy or imaging when performed (e.g., 63663, 63664, 64596–64598)
Coding cross‑referenceSee coding lists for selected CPTs, additional CPTs, and HCPCS/L codes relevant to implantation and supplies
Documentation noteImaging/guidance use should be documented when billed as part of the procedure
inv-183: PNS (up to 60 days) and PENFS (5 days) trial durations
Temporary PNS and PENFS durationsTemporary percutaneous PNS trials commonly up to 60 days; auricular PENFS devices left for ~5 days in postoperative trials
Background and Scope
Background: Electrical stimulation modalities deliver currents transcutaneously or via implanted leads for purposes including pain relief, muscle contraction, and rehabilitation. FES produces coordinated muscle contractions for functional activities (standing, ambulation), while TENS, NMES, PENS, PNS, PEMF, and other modalities are used variably for analgesia, muscle strengthening, or tissue healing. Evidence quality and clinical indications vary widely across modalities, which underpins the policy's differentiated coverage stance.
Policy Revision History
May 1, 2026policy_effective_dateLatest
Policy effective date for this UnitedHealthcare Nebraska electrical stimulation coverage policy set to May 1, 2026.
2025-11-21reference_update
Nebraska DHHS DMEPOS Chapter 7 referenced for state-specific coverage criteria and codes (accessed Nov 21, 2025).
Policy Summary
PayerUnitedHealthcare
PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Nebraska Only)
Policy CodePolicy CS036NE.U
Change TypeNo material change
Effective DateMay 1, 2026
Next Review Date
Key ActionDocument prior conservative therapies and objective baseline measures when requesting prior authorization for indication‑specific electrical stimulation therapies.
Musculoskeletal/postoperative: NMES combined with conventional rehabilitation has been associated with improved quadriceps strength and some functional outcomes after joint replacement and ACL surgery; effects on ROM are limited and heterogeneous.
Sun et al.; Li et al.; Zhao et al.
Poststroke motor recovery:
Systematic reviews/meta-analyses report NMES can improve activities of daily living poststroke with stronger signals in subacute stage and for upper extremity; effects on motor ability are less clear.
Kristensen et al.; Loh et al.; Eraifej et al.
Poststroke dysphagia: Multiple systematic reviews (including 46 RCTs) report NMES combined with swallowing therapy can improve swallowing function and quality of life, though studies are heterogeneous and frequently from single countries.
Wang et al.; Zhang et al.
Neuromodulation and language/aphasia: Small RCTs combining NMES with language training show cortical activation changes and correlated clinical improvement in aphasia but require validation in larger studies.
Xie et al.
Low Back Pain (transcutaneous electrotherapies): TENS shows no consistent benefit; IFT may provide short-term pain and disability improvement in some trials but overall evidence is limited and heterogeneous; EMS results are mixed and largely short-term.
Wolfe et al.; Rampazo et al.; Hussein et al.
Knee Osteoarthritis and Post-TKA: IFT and PEMF trials show mixed short-term pain/function signals in knee OA; network analyses and some RCTs show no consistent superiority; larger, high-quality RCTs needed.
Chen et al.; Kadı et al.; Yang et al.
Ontario Health; Goree et al.; Hatheway et al.
evidence: Picelli et al. review of 3 RCTs
Picelli et al.
Postoperative use (e.g., after UKA): Some single RCTs report improved pain/function with prolonged PEMF after certain arthroplasty procedures, but methodological limitations warrant cautious, case-by-case consideration with documentation of clinical benefit.evidence: D'Ambrosi RCT (small sample)
D'Ambrosi et al.; Yabroudi et al.
Other indications (MS fatigue, neck pain): Evidence for PEMF in indications such as MS-related fatigue or chronic neck pain is inconsistent or negative; routine coverage not supported without stronger evidence.
Trial-level negative findings cited
PurposeDemonstrates ability to maintain upright support posture as required for FES-assisted ambulation
Documentation noteMust be demonstrated prior to coverage consideration per FES criteria
inv-60: Responder threshold (≥50% pain reduction used in some PNS RCTs)
Responder threshold used in PNS RCTs>= 50% reduction in pain (common primary responder definition)
ExamplesSPRINT and other temporary PNS trials reported responder outcomes defined as >=50% pain relief
Alternate responder definitionsSome studies also report >=30% as clinically meaningful; check trial-specific endpoints
Scrambler therapy — prior authorization recommended given guideline caution and low/variable evidence
Prior Authorization
Prior authorization expectations
Prior authorization expectations include submission of clinical eligibility, prior conservative therapy history, trial results (when applicable), and device-specific details (device model, stimulation parameters, planned implant vs temporary lead). For some technologies (e.g., NMES for dysphagia), governance/research requirements from NICE may affect coverage decisions and documentation expectations.
Provide prior conservative therapy attempts and durations
Provide results of temporary trial PNS or documented response to temporary PNS (e.g., ≥30% pain reduction or device-specific responder criteria)
Document device model and intended therapy parameters (e.g., stimulation dose, frequency, duration)
Documentation Required
Prior authorization: record of clinical eligibility and treatment parameters
Prior authorization requests should include a detailed record of clinical eligibility and treatment parameters: diagnosis, symptom duration and severity, objective findings (imaging/physiologic testing when required), previous conservative therapies (types and durations), trial stimulation results (if performed), planned device and programming parameters, and the proposed care plan including follow-up and outcome measures.
Diagnosis with supporting imaging or tests (when applicable)
Symptom duration and prior conservative treatment dates (e.g., >90 days medical management and PT for ReActiv8)
Prior authorization for PNS — trial data and conservative therapy
For peripheral nerve stimulation (PNS), prior authorization should request trial data (temporary or percutaneous trial results) and documentation of failure of conservative therapies (typically two or more noninvasive treatments and an adequate course of PT/medication).
Documented conservative therapies attempted and failed (types and durations)
Temporary PNS/SPRINT trial results (responder thresholds, duration of trial)
Indication aligned with ASIPP or other guideline recommendations
Prior Authorization
Prior authorization recommended for ReActiv8
Prior authorization is recommended for ReActiv8 restorative neurostimulation given device cost, implant nature, and specified trial inclusion criteria. Request documentation of prior conservative management (e.g., >90 days), objective evidence of multifidus dysfunction (imaging/physiologic testing), and prior PT attempts.
>90 days medical management and at least one course of physical therapy
Objective evidence of multifidus dysfunction (imaging or physiologic testing)
Clinical measures consistent with trial eligibility (e.g., ODI and NRS thresholds used in RESTORE/ReActiv8 trials)
Prior Authorization
Scrambler therapy prior authorization
Scrambler therapy should generally be subject to prior authorization due to low or inconsistent evidence and guideline recommendations that limit routine use. Authorization should include indication, prior therapies, and rationale for selecting scrambler therapy over alternatives.
Indication and supporting documentation (e.g., CIPN or chronic neuropathic pain)
Prior conservative and pharmacologic therapies attempted
Planned treatment regimen (number of sessions and device model)
Prior Authorization
Prior authorization for restorative neurostimulation
Prior authorization is recommended for restorative neurostimulation implants (e.g., ReActiv8) to ensure selection matches trial and FDA-labeled criteria and that conservative management has been appropriately attempted.
Submit trial and conservative therapy documentation per ReActiv8 labeling and trial inclusion criteria
Provide baseline outcome scores (ODI, NRS) and prior therapy dates
Denial Risk
Documentation-driven denial risk
Denials are frequently documentation-driven. Insufficient or missing medical record documentation (lack of prior therapy history, absent objective findings, missing trial results, or unclear diagnosis/duration) increases denial risk.
Incomplete documentation is a common basis for claim denial
Note
Not directly stated in these chunks; no administrative submission details
Not directly stated in these chunks: specific administrative prior authorization forms, payer fax numbers, or portal submission instructions. Providers should consult the payer's provider portal or prior authorization guidelines for operational details.
No payer-specific submission workflow provided in the excerpt
Denial Risk
Evidence insufficiency may trigger denial
Evidence insufficiency or limitations in the clinical literature (heterogeneous protocols, small samples, short follow-up, industry-sponsored data) may trigger denial or requests for additional information. Be prepared to supply rationale and higher-quality supporting evidence when available.
Heterogeneous evidence and short-term trials may lead to coverage denials
Industry-sponsored studies and high risk-of-bias trials increase scrutiny
Denial Risk
Evidence limitations may trigger denial or restricted authorization
Evidence limitations (low-quality studies, inconsistent outcomes, and lack of long-term durability data) may affect authorization decisions for technologies such as PENS, PNS, PEMF for fracture healing, and scrambler therapy.
Be prepared to document comparative benefit vs conservative care
Provide long-term outcomes when available to support requests
Note
No explicit administrative prior authorization process stated
No explicit administrative prior authorization process or universal prior authorization requirement is described in these excerpts. Providers must verify payer-specific requirements separately.
Check UnitedHealthcare provider resources for exact prior authorization procedures
Note
Governance/Research requirement (NICE)
NICE guidance for certain indications (e.g., NMES for dysphagia) requires use only with special arrangements for clinical governance, consent, audit, or research — this may translate into additional documentation or restricted coverage expectations by payers.
NMES for dysphagia: report indication, patient selection, consent, outcomes, and adverse events per NICE special arrangements
Denial Risk
Potential denial when IFT is billed as adjunct without demonstrated added benefit
Potential denial may occur when interferential therapy (IFT) or similar modalities are billed as an adjunct without demonstrated added benefit over standard therapy. Authorization should document the expected incremental benefit of the modality.
When billing IFT as adjunctive therapy, document specific expected clinical improvement and prior standard treatments
Denial Risk
Guideline-based denial risk for PENS in LBP
Guideline-based denial risk exists for PENS in low back pain (NICE recommends against PENS for LBP/sciatica); prior authorization requests should address guideline conflicts and provide strong supporting evidence if PENS is requested.
NICE recommendation against PENS for LBP — include rationale and evidence if requesting coverage
Prior Authorization
Evidence limitations may affect authorization decisions
Evidence limitations may affect authorization for implantable PNS and other devices where current literature is limited by small, heterogeneous trials. Provide device-specific RCT data and real-world outcomes when possible.
Include RCT results, registry data, and follow-up outcomes where available to support authorization
Denial Risk
PEMF for Fracture Healing — denial risk
Pulsed electromagnetic field (PEMF) therapy for fracture healing carries a denial risk in some contexts due to mixed or negative RCT results; prior authorization should include fracture type, radiographic nonunion status, and rationale for PEMF use.
For PEMF requests, submit radiographic evidence, prior management, and RCT-based rationale
Note
This excerpt contains reference citation
This excerpt includes many reference citations and evidence reviews (Hayes, ECRI, NICE, ASIPP, ASCO, ESMO). When submitting prior authorization, include relevant independent evidence reports or guidelines cited in support of the requested therapy.
Hayes, ECRI, NICE, ASIPP, ASCO, Ontario Health and other evidence reports are referenced in the policy excerpt
Documentation Required
Required medical documentation
Required medical documentation for reviews includes relevant medical history, physical examination findings, diagnostic test results, prior therapy details, and legible records supporting medical necessity.
Medical history and physical exam
Pertinent diagnostic tests or imaging
Prior treatment records with dates and responses
Documentation Required
Clinical trial eligibility examples
Clinical trial eligibility examples cited in trial reports and RCTs can guide authorization documentation (for example: ability to evoke electrically stimulated contraction, recent SCI <6 months in some trials, ODI/NRS thresholds for restorative neurostimulation trials). Include these trial-aligned data points when applicable.
Ability to evoke contraction in target muscle group (trial eligibility)
Recent SCI < 6 months for some restorative FES trials
ODI and NRS thresholds used in ReActiv8/RESTORE trial enrollment
Documentation Required
Suggested supporting documentation elements
Suggested supporting documentation elements include diagnosis confirmation, recovery phase (acute/subacute/chronic), device type, previous therapy details, trial outcomes, and objective measures (e.g., gait parameters, strength grades, imaging).
Suggested supporting documentation (additional): baseline functional scores, medication history and stability, prior rehabilitation specifics, and adverse event reporting. These details strengthen prior authorization submissions.
Baseline and recent functional scores (e.g., VAS, ODI, LEFS, WOMAC)
Stable medication regimen dates
Rehabilitation program details and adherence
Documentation Required
Documentation for NMES in dysphagia
Documentation expectations for NMES in dysphagia (per NICE) include indication, patient selection criteria, consent that acknowledges limited evidence, planned outcome measures, and arrangements for governance, audit, or research reporting.
Record indication and selection criteria for NMES in dysphagia
Document informed consent describing limited evidence and monitoring plan
Include planned outcome measures and audit/research arrangements
Documentation Required
Outcome measure documentation
Outcome measure documentation should include validated scales appropriate to the indication (examples: VAS/NRS for pain, ODI for low back disability, LEFS/WOMAC for lower extremity function, 6MWT/TUG for gait/endurance). Include baseline and planned follow-up times.
Pain scores (VAS or NRS) baseline and follow-up
Disability/function scores (ODI, LEFS, WOMAC)
Mobility/endurance tests (6MWT, TUG)
Documentation Required
Suggested clinical documentation to support therapy
Suggested clinical documentation to support neuromodulation or electrical stimulation therapies includes indication, prior therapies and response, baseline outcome measures, trial stimulation results, planned therapy parameters, and follow-up schedule.
Indication and prior therapy history
Baseline outcome measures and planned reassessment intervals
Trial stimulation documentation and responder thresholds
Documentation Required
Prior therapy, baseline scores, and stable meds
Document prior therapy, baseline scores, and any stable medication regimens. Where medications were used in combination, indicate stability of doses and any changes during trials.
List prior therapies with dates and responses
Provide baseline scores and dates (e.g., ODI, NRS)
Document medication stability during trial periods
Documentation Required
Required clinical documentation examples
Required clinical documentation examples include trial durations, follow-up visits, objective outcome reporting, and adverse event documentation. Include timeframe benchmarks used in trials (e.g., 8–12 weeks for many FES studies, 60 days for temporary PNS trials).
Trial durations and dates (e.g., 60-day PNS, 8-week FES)
Follow-up visit schedule and outcome reporting
Adverse event reporting
Documentation Required
Postoperative PEMF documentation
Postoperative PEMF documentation should include fracture type, radiographic union status, dates of surgery, prior interventions, and objective radiographic and clinical outcomes to justify continued use.
Radiographic evidence of delayed union/nonunion
Dates of surgery and prior management steps
Objective clinical and radiographic follow-up data
Documentation Required
Suggested documentation elements
Suggested documentation elements for device implantation or high-cost therapies: indication, conservative care attempts, objective testing, trial responses, device model and planned parameters, follow-up and outcome measures, and disclosure of device-related risks.
Complete conservative care history and rationale for escalation
Objective testing and trial response documentation
Device model, planned programming parameters, and follow-up plan
Note
Supporting evidence reports
Supporting evidence reports referenced in the excerpt include Hayes, ECRI, Ontario Health, NICE, ASIPP, ASCO, and guideline or HTA documents. Attach relevant external assessments when submitting complex or investigational device requests.
Hayes, ECRI, Ontario Health assessments cited in the policy excerpt
NICE, ASIPP, ASCO/ESMO guideline references
Step Therapy
No step therapy requirements are specified
No step therapy requirements are specified in this section. However, multiple excerpts recommend a conservative-first approach and documented trials of noninvasive therapies prior to implantable or long-term device use.
No formal step therapy rules stated; conservative-first approach emphasized
Step Therapy
Consider conservative device/therapy trial prior to long-term FES
Consider documenting a conservative device or therapy trial prior to approval of long-term FES or implantable neuromodulation (examples include documented AFO trial before long-term FES for foot drop, or structured PT before restorative neurostimulation).
AFO trial documentation for foot drop vs assistive FES
Structured PT program details and adherence before device implant
Step Therapy
Conservative therapy before FES/NMES
Conservative therapy prior to FES/NMES is commonly documented in trials and guidance — prior authorization should include evidence of adequate conservative therapy and rehabilitation efforts.
Document supervised exercise/physical therapy programs and durations prior to device therapy
Step Therapy
Step therapy: NMES adjunct to pulmonary rehab
Step therapy: NMES should not replace comprehensive pulmonary rehabilitation for COPD; NMES is generally considered an adjunct and prior authorization requests should document the relationship to pulmonary rehab.
NMES as adjunct to pulmonary rehabilitation — document concurrent rehab and rationale
Step Therapy
Conservative therapies required before PNS
Conservative therapies are typically required before PNS in policy contexts and guideline recommendations (ASIPP suggests refractory pain after two or more conservative treatments before implantable PNS). Prior authorization should reflect that sequence.
Document failure of ≥2 conservative treatments prior to considering implantable PNS
Step Therapy
Conservative therapy before PEMF
Conservative therapy before PEMF is often expected (for example, a trial of structured exercise/PT before PEMF use for musculoskeletal conditions). Provide documentation of prior standard care attempts.
Submit records of prior structured exercise or PT programs before PEMF requests
Step Therapy
Conservative therapy before implantation
Conservative therapy before implantation is an informational requirement emphasized for restorative neurostimulation and many implantable neuromodulation devices; prior authorization should document medical management and PT attempts (often >90 days).
>90 days of medical management and at least one course of physical therapy documented before ReActiv8 implantation
Note
Conservative therapy requirement (informational)
A conservative therapy requirement is presented as informational across multiple device categories; include dates, therapies, and responses when submitting for authorization.
Provide conservative therapy list, dates, adherence, and documented outcomes
Step Therapy
Conservative therapy before implant
Conservative therapy before implant is consistently emphasized for restorative neurostimulation, PNS, and other implantable devices. Prior authorization reviewers expect documentation of adequate conservative management prior to approval.
Document conservative management steps and failure prior to implant requests
Conservative-first approach: Conservative therapies (exercise programs, multidisciplinary rehabilitation) are preferred first‑line per ACP and NICE guidance and should be documented prior to considering electrotherapy modalities for chronic conditions.
Guideline-based recommendation
Documented trial of conservative therapy recommended before PENS
Prior conservative therapy before PENS: Documented trial of guideline-recommended conservative therapy (e.g., PT, medications) is recommended before considering PENS, consistent with guideline notes that PENS is not first‑line for low back pain.
Hayes and NICE assessments; systematic reviews
Documentation of failure of CMM is a common precondition in trials and reviews
Documentation of failure of CMM: Documentation of failure of conventional medical management (CMM) — such as medications and supervised rehabilitation — is a common precondition in trials and reviews for percutaneous PNS and should be recorded prior to device consideration.
Ontario Health, Hatheway et al., and other HTAs/trials
Failure of ≥2 conservative therapies (ASIPP recommendation)
Failure of ≥2 conservative therapies: Failure of two or more conservative therapies is commonly required prior to implantable PNS per ASIPP guidance and trial practice.
ASIPP recommendation
Trial of conventional PT/exercise recommended before adjunctive PEMF
PT/exercise before PEMF: A trial of conventional progressive resistance exercise or structured physical therapy is recommended before adjunctive PEMF therapy for knee or spine conditions; document the exercise/PT course and response.
PEMF trials commonly used exercise comparators; Yabroudi et al.; Kull et al.
Documented failure of conservative measures prior to consideration of implantation (>90 days medical management and PT)
Documented failure prior to implant: Documented failure of conservative measures prior to consideration of restorative neurostimulation implantation (typically >90 days of medical management plus at least one attempt at physical therapy) is expected based on trial eligibility and device indication.>90 days (medical management) and at least one PT attempt
ReActiv8 trial inclusion and PMA indication
Recommend documentation of prior trials of guideline-recommended conservative therapies before considering scrambler therapy
Prior trials before scrambler therapy: Recommend documentation of prior trials of guideline-recommended conservative therapies (e.g., pharmacologic neuropathic pain treatments) before considering scrambler therapy; consider use in clinical trials when guideline bodies advise against routine use.
ASCO/ESMO guidance and systematic reviews
Peripheral nerve field stimulation (PNFS): implantation of electrode arrays within subcutaneous tissue to stimulate a painful field rather than a discrete peripheral nerve
Device examplesSystems referenced include StimRouter, SPRINT, Freedom, Nalu in evidence summaries
inv-179: FES training program in CHF RCT — 6 weeks example
Example FES training duration6 weeks (example FES training program in a CHF randomized controlled trial)
Measured outcomesStudy followed participants for up to 19 months for hospitalization and mortality endpoints
ContextTrial-era program length used as an illustrative regimen for FES cardiac training programs
inv-180: NMES sessions described in trials (e.g., up to 20 sessions over 5 days in THR feasibility RCT)
NMES session example (orthopedic post-op)Up to 20 sessions over 5 days (minimum 30 minutes per session) reported in a THR feasibility RCT
Typical measuresPostoperative pain (VAS), limb swelling (circumference) measured at multiple early timepoints
Study limitationsShort follow-up, small sample size, single-center design in the cited feasibility trial
inv-181: IFT/MENS references for session examples
IFT/MENS session referencesIFT and MENS trials report variable session counts and heterogeneous protocols across RCTs and systematic reviews
Evidence summarySystematic reviews cite short-term pain relief in some IFT trials but overall heterogeneity and inconsistent added benefit when combined with standard care
MENS evidenceMENS studies are small and limited; no standardized session frequency established in the cited reviews
inv-182: PENS / MENS study session variability (single to 16 sessions)
PENS/PENS session variabilitySession counts in trials varied widely—from a single session up to 16 sessions depending on indication and study design
Example ACL studyTwo ultrasound‑guided femoral nerve PENS sessions plus 12‑week rehab in an ACL RCT showing short‑term pain reductions
Evidence limitationsSmall sample sizes and short follow-up limit conclusions about optimal dosing
inv-183: PNS (up to 60 days) and PENFS (5 days) — trial durations described
PNS trial durationsTemporary percutaneous PNS leads left in situ up to 60 days in several trials; PENFS auricular devices commonly left for 5 days in postoperative studies
Evidence examplesGoree et al. 60‑day PNS TKA RCT with leads removed at 8 weeks; Ilfeld et al. auricular PENFS left in situ for 5 days post‑TKA
Follow-upSome PNS trials include follow-up out to 12 months and longer to assess durability
inv-184: Percutaneous PNS temporary trials commonly last 60 days
Common temporary PNS trial length60 days is a commonly reported duration for percutaneous PNS temporary trials
Implanted PNS follow-upImplanted percutaneous PNS studies report follow-up visits out to 12 months and beyond to evaluate durability
Protocol noteTrial endpoints often assess responder proportion (e.g., >=50% pain reduction during weeks 5–8)
inv-185: PEMF therapy examples (2–7 sessions/week; 30–45 min/session; 4 hr/day for 60 days example)
PEMF session examplesStudy regimens varied: 2–7 sessions/week; 30–45 minutes per session; one implant‑adjunct example used 4 hours/day for 60 days
Indication variabilityPEMF parameters (frequency, intensity, session duration) differed across trials for LBP, OA, and postoperative indications
Clinical outcomesSome RCTs reported short‑term pain and function improvement while others found no added benefit versus exercise alone
inv-186: No explicit frequency limits provided for restorative neurostimulation implants in these chunks
Restorative neurostimulation frequency limitsNo explicit frequency or session‑count limits provided for restorative neurostimulation implants in these chunks
Trial usage patternRESTORE/ReActiv8 trials programmed patients to use stimulation sessions twice daily (example: 30 minutes twice daily in some studies)
Documentation noteCoverage conditions reference trial‑like eligibility rather than per‑procedure frequency caps
inv-187: Percutaneous PNS and related procedures — no frequency limits specified here
Percutaneous PNS procedural frequency limitsNo specific frequency limits specified for percutaneous PNS or related procedures in this segment
Trial normsTypical temporary protocols involve 60‑day stimulation with daily use recommendations (e.g., 6–12 hours/day in some cohorts)
Coverage implicationAuthorization decisions reference trial durations and documented response rather than fixed billing frequency limits
Note
Note
Note
Note
Note
Note
Note
Additional placeholder entries note the modalities considered not medically necessary in the policy excerpt; no new procedural details are provided in these duplicates.
Duplicate placeholder reiteration indicating multiple electrotherapy modalities are judged not medically necessary in the excerpt.
Another duplicate placeholder restates the list of modalities the policy considers not medically necessary due to insufficient evidence.
While many 'not covered' placeholders are present, the excerpt does not list explicit procedural codes or named procedures as universally not covered. The policy does explicitly note that PEMF is hypothesized to facilitate biological repair but that routine use for fracture healing is not supported by current evidence.
Duplicate placeholder reiterating modalities considered not medically necessary in the document excerpt.
Duplicate placeholder reiterating the policy's list of unproven electrotherapies deemed not medically necessary in this excerpt.
Duplicate placeholder entry repeating the policy characterization of several electrical stimulation approaches as not medically necessary.
Duplicate placeholder entry reflecting modalities considered not medically necessary in the provided excerpts.
Duplicate placeholder restating unproven modalities that the policy lists as not medically necessary in the excerpt.
Duplicate placeholder reflecting the policy excerpt's categorization of multiple modalities as not medically necessary.
Duplicate placeholder reiteration of the policy's list of unproven and not medically necessary modalities.
Duplicate placeholder restatement that the excerpt treats various electrotherapy and neuromodulation modalities as not medically necessary in the absence of stronger evidence.
The policy explicitly states that routine coverage of many PNS systems is not supported because of limited, low‑quality, and heterogeneous evidence; per the cited HTAs, careful patient selection and additional high‑quality trials are required before routine coverage is appropriate.
Duplicate placeholder entry reiterating the policy's unproven modalities list and that these are considered not medically necessary in the excerpted content.
Duplicate placeholder restating that multiple electrotherapy modalities are currently considered not medically necessary in the policy excerpt.
Duplicate placeholder reiterating noncovered modality listings in the excerpt due to insufficient evidence.
Duplicate placeholder entry restating that the policy identifies several modalities as not medically necessary given current evidence limitations.
Duplicate placeholder reiteration of the policy categorizing several electrical stimulation modalities as not medically necessary within this excerpt.
The excerpt does not declare explicit 'not covered' procedural items tied to billing codes. It does, however, highlight evidence limitations for implanted‑electrode FES and other modalities and identifies PEMF and many PNS systems as lacking consistent high‑quality evidence to support routine coverage.
Used after surgery, neurological injury, or disabling conditions to improve muscle function and strength
DistinctionNMES is distinct from TENS which primarily targets pain modulation rather than muscle contraction
inv-124: PENS
PENS definitionPercutaneous electrical nerve stimulation: insertion of acupuncture‑like needles connected to an external power source to deliver electrical stimulation for pain
MechanismTheory: modulation of hypersensitive peripheral nerves and endogenous opioid‑like pathways; differs from TENS by being percutaneous
Procedure noteNeedle placement may be ultrasound guided in some trials
inv-125: Percutaneous electrical nerve field stimulation
PENFS definitionPercutaneous electrical nerve field stimulation: percutaneous auricular/nerve‑field stimulation targeting central pain pathways (auricular vagus branch) using low‑voltage alternating frequencies
Clinical useStudied for postoperative analgesia and DGBI; devices like NSS‑2 Bridge applied for multi‑day stimulation (e.g., 5 days)
Evidence statusEvidence limited and heterogeneous; Hayes and other reviews rate support as unclear for many indications
inv-126: PNS
PNS definitionPeripheral nerve stimulation: electrode(s) implanted or placed near a peripheral nerve to modulate pain signal transmission
FormsIncludes temporary percutaneous leads (e.g., SPRINT) and implanted or permanent systems (e.g., StimRouter, Freedom, Nalu)
Evidence noteEvidence varies by system and indication; many studies are small and heterogeneous
inv-127: Peripheral nerve field stimulation
PNFS/PSFS definitionPeripheral nerve field stimulation: implantation of electrode arrays within subcutaneous tissue to stimulate a painful field when discrete nerves do not map to the pain area
Use casesUsed for localized chronic back pain and other focal painful areas as adjunct or alternative to SCS in some studies
Evidence statusLimited evidence consisting of small trials and case series; more robust trials needed
inv-130: TENS
TENS definitionTranscutaneous electrical nerve stimulation: surface electrodes deliver current through skin to decrease pain perception via peripheral nerve activation or endorphin release
DistinctionTENS differs from NMES/FES which aim to evoke muscle contractions
Regulatory statusTENS devices are FDA Class II devices (product codes referenced) and widely available
inv-132: Restorative Neurostimulation
Restorative neurostimulation definitionMinimally invasive stimulation of the multifidus muscle via self‑anchoring leads beside the medial branch of the dorsal ramus to rehabilitate multifidus control for mechanical CLBP
Device exampleReActiv8 Implantable Neurostimulation System (PMA) indicated for intractable CLBP with multifidus dysfunction
Therapeutic goalRestore neuromuscular control rather than provide continuous analgesic neuromodulation
inv-133: Scrambler Therapy
Scrambler therapy definitionNoninvasive transdermal treatment applying electrodes to the dermatome to deliver variable nonlinear waveforms intended to present nonpain information to the painful area
Typical regimenProtocols often involve daily sessions over 2 weeks (e.g., ten 45‑minute sessions) in many trials
Evidence/guideline noteSystematic reviews report mixed, low‑quality evidence; guideline bodies recommend use within trials for some indications
inv-134: Pulsed Electromagnetic Field Stimulation
PEMF definitionPulsed electromagnetic field stimulation: noninvasive application of pulsed electromagnetic fields hypothesized to facilitate bone/cartilage repair and modulate inflammation
Protocol variabilityFrequencies, intensities, session durations and course lengths vary widely across trials
Evidence noteInsufficient high‑quality evidence for many indications; some RCTs report short‑term benefit in OA or LBP but results are inconsistent
inv-136: Contralaterally controlled FES (CCFES)
CCFES definitionContralaterally controlled FES: movement of the unaffected limb controls stimulation of the affected limb to assist motor recovery
Use caseStudied for poststroke upper extremity rehabilitation and compared with conventional NMES in RCTs/meta-analyses
Outcome signalsSome trials show greater improvements in motor scores vs NMES but study heterogeneity exists
inv-137: Ankle-foot orthosis (AFO) definition
AFO definitionAnkle‑foot orthosis: conservative orthotic device used to manage foot drop and gait disorders; commonly used as comparator in FES studies
Comparative roleTrials compare FES vs AFOs for gait outcomes to inform rehabilitation choices
Documentation notePrior use of an AFO is reasonable to document before long‑term device implantation in some contexts
inv-139: Foot-drop FES
Foot‑drop FESFES applied to peroneal nerve or tibialis anterior to improve dorsiflexion during gait in stroke or MS-related foot drop
Evidence summaryMeta-analyses show improvements in ankle dorsiflexion, balance, and some gait parameters when combined with supervised therapy
Clinical considerationEffect on gait speed is inconsistent; benefit more likely when combined with PT and in earlier recovery phases
inv-142: Interferential therapy (IFT)
Interferential therapy (IFT)Transcutaneous electrotherapy using crossing medium‑frequency currents intended to reduce pain and improve function; evidence heterogeneous
Evidence stanceSystematic reviews find mixed short‑term benefits for some conditions but overall heterogeneity and guideline caution (NICE recommends against for OA/chronic primary pain)
Typical session reportingTrials reported variable session counts; no standardized frequency limit established
MENS (microcurrent) definitionLow‑amplitude microcurrent electrical stimulation investigated for pain and healing; evidence limited to small RCTs and case series
Study dosingTrials have used daily multi‑hour applications (e.g., 3 hours/day in Lawson et al.); session counts vary by study
Evidence cautionMeta‑analyses note small sample sizes and need for larger RCTs to confirm effects
inv-145: PENS (alternate entries)
PENS alternate notesPENS involves percutaneous needle electrodes; some trials used ultrasound guidance and reported short‑term pain/function improvements
Session variabilityProtocols ranged from single session studies to multi‑session interventions (up to 16 sessions in some research)
Evidence qualityOverall quality is low and larger robust trials are recommended
inv-147: PENFS / auricular neuromodulation
PENFS (auricular) notesPercutaneous auricular neuromodulation (PENFS) uses percutaneous leads applied to the ear, commonly left in situ for multi‑day postoperative analgesia trials
Example deviceNSS‑2 Bridge used in TKA pilot RCT with 5‑day left‑in‑situ application
Evidence statusSmall RCTs and registries suggest opioid‑sparing effects but larger trials are needed
inv-149: PNS (alternate entries)
PNS alternate notesPNS includes temporary percutaneous and implanted permanent systems; evidence is mixed and device‑specific
Typical trial endpointsPain reduction percentages (>=30% or >=50%), functional improvements, and durability up to 12 months reported in some studies
Regulatory contextSome systems have varying levels of evidence and ongoing HTAs (Hayes, ECRI, Ontario Health) consider additional data necessary
Percutaneous PNS definitionMinimally invasive placement of percutaneous leads to stimulate peripheral nerves for analgesia; common protocols include 60‑day temporary stimulation
Typical daily useSome studies instructed 6–12 hours/day of stimulation during the treatment period
Outcome measuresResponder rates (>=50% pain reduction) and functional gains are commonly reported endpoints
inv-151: Peripheral nerve field stimulation (PNFS)
PNFS definition (alternate)Subcutaneous field stimulation targeting localized painful areas when a single peripheral nerve does not account for the pain distribution
Clinical evidenceLimited to small trials and case series; comparative data to SCS or other modalities are sparse
Use considerationSometimes used as adjunct to SCS for refractory back pain in select cases
inv-152: PEMF stimulation definition
PEMF stimulation definitionExternal pulsed electromagnetic fields applied noninvasively with variable frequencies and intensities intended to modulate biological processes for pain and tissue repair
Parameter heterogeneityTrials report wide ranges (e.g., 3–50 Hz; 1.5 mT; session durations 10–30 minutes up to multi‑hour regimens)
Evidence statusSystematic reviews find inconsistent benefits across indications and call for more robust RCTs
inv-154: Restorative neurostimulation (ReActiv8)
ReActiv8 (restorative) definitionImplantable neurostimulation system indicated to restore multifidus muscle function for mechanical CLBP associated with multifidus dysfunction (PMA‑approved ReActiv8)
Indication specificsBilateral stimulation of L2 medial branch at L3; requires evidence of multifidus dysfunction and prior failure of therapies incl. PT and meds
inv-155: Refractory mechanical CLBP with impaired multifidus control definition
ReActiv8 trial populationPatients with refractory mechanical CLBP failing >90 days medical management and at least one PT attempt (ODI 30–60; NRS 6–9)
Expected outcomesTrials reported clinically meaningful improvements (e.g., >=50% pain reduction in a substantial proportion) and durable benefits at multi‑year follow‑up
Documentation neededEvidence of multifidus dysfunction by imaging/physiologic testing and prior conservative therapy failure
inv-156: Scrambler therapy definition
Scrambler therapy summaryNoninvasive neuromodulation delivering variable nonlinear waveforms via skin electrodes for neuropathic pain; studied in multiple small RCTs and series
Typical regimenOften delivered as ten 45‑minute sessions over 2 weeks in published RCTs
Evidence/guideline noteSystematic reviews report mixed low‑quality evidence; guideline bodies (ASCO/ESMO) recommend use only in trials for CIPN
PoNS (translingual) definitionPortable nonimplantable device delivering electrotactile stimulation to the tongue used with targeted PT for balance/gait rehabilitation
Typical program5‑week programs combining PoNS with PT have been used in RCTs for mmTBI and MS with logged adherence
Evidence statusRCTs show improvements in balance/gait when combined with PT but overall evidence considered inconclusive by some assessments
inv-159: TENS / Microcurrent devices regulatory status
TENS/Microcurrent regulatory statusTENS and microcurrent devices are FDA‑regulated Class II devices (product codes referenced)
Coverage implicationDevice regulatory class does not by itself establish coverage; clinical evidence determines medical necessity
Coding referencesProduct and device codes are listed in the policy's device/FDA references section
PNS summaryPeripheral nerve stimulation: includes temporary percutaneous and implanted systems; commonly evaluated with 60‑day temporary trials and responder endpoints of >=50% pain reduction
Evidence variabilityStudy designs range from RCTs to case series; systematic reviews note low to moderate quality and heterogeneity
Common adverse eventsLocalized mild events such as skin irritation and lead migration; serious device‑related events are uncommon in reported trials
Restorative neurostimulation (alternate)Implantable system intended to rehabilitate dysfunctional musculature (multifidus) with trial evidence showing substantial improvements in ODI and NRS at 1 year
Usage pattern from trialsParticipants instructed to activate device for set sessions (e.g., 30 minutes twice daily) with programmed stimulation parameters post‑implant
Long‑term dataFollow‑up studies report durable benefit up to 4–5 years in subsets though some studies note attrition and explants
Example trials
Goree et al. 60‑day PNS TKA RCT; Ilfeld et al. auricular PENFS TKA pilot with 5‑day device in situ
Follow‑up practicePlacebo groups often crossed over after trial period with subsequent follow‑up to 12 months in some studies
inv-179: Example trial length — FES training in CHF RCT (6 weeks)
FES CHF trial example duration6‑week FES training program used in a randomized placebo‑controlled CHF trial
Outcomes measuredPeak VO2, hospitalizations, and long‑term follow‑up (median 383 days) for clinical endpoints
InterpretationUsed as an illustrative example of program length in cardiac FES literature
inv-181: IFT/MENS session examples
IFT/MENS session examplesTrials of IFT and MENS report varied session frequencies and durations; systematic reviews summarize heterogeneous protocols without standardized limits
Clinical implicationNo consensus frequency limits; utilization review should reference trial protocols and guideline statements
DocumentationWhen used, document session counts, device parameters, and objective outcome measures to support medical necessity